This inventor holds 2 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: Grifols Therapeutics Inc.. Active years: 2012-2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2012-2014
Title: The Innovations of Philip Scuderi, Jr.
Introduction
Philip Scuderi, Jr. is an accomplished inventor based in Chapel Hill, NC (US). He has made significant contributions to the field of medical treatments, particularly in relation to amyloid deposition and ophthalmic indications. With a total of 2 patents, his work has the potential to impact various therapeutic approaches.
Latest Patents
One of his latest patents is titled "Method of treatment and prophylaxis of diseases related to amyloid deposition using IgM." This invention focuses on a method for treating or preventing diseases associated with β-amyloid polypeptides through the administration of an immunoglobulin preparation enriched in immunoglobulin M (IgM). Additionally, he holds a patent for "Recombinant plasmin for ophthalmic indications." This patent provides methods for using polynucleotides and polypeptides related to a recombinantly-modified plasmin(ogen) molecule, which is significant for procedures like vitrectomy or vitreolysis.
Career Highlights
Philip Scuderi, Jr. is currently associated with Grifols Therapeutics Inc., where he continues to innovate and develop new medical solutions. His work is characterized by a strong focus on improving treatment methodologies and enhancing patient outcomes.
Collaborations
Throughout his career, Philip has collaborated with notable professionals in the field, including Vikram Arora and Jennifer Audrey Hunt. These collaborations have further enriched his research and development efforts.
Conclusion
Philip Scuderi, Jr. exemplifies the spirit of innovation in the medical field through his patents and ongoing work at Grifols Therapeutics Inc. His contributions are paving the way for advancements in treatment methodologies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
